{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:14:20Z","timestamp":1783354460678,"version":"3.54.6"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"DOI":"10.7759\/cureus.112146","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:17:57Z","timestamp":1783351077000},"source":"Crossref","is-referenced-by-count":0,"title":["Biosimilar Nivolumab-Based Combination Therapy in Advanced Oral Cavity Squamous Cell Carcinoma: A Real-World Case Series of Five Patients"],"prefix":"10.7759","author":[{"given":"Santhosh","family":"Meedimale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya  S","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipulkumar","family":"Thummar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21193","article-title":"Oral cavity cancer in developed and in developing countries: population-based incidence","volume":"32","author":"de Camargo Cancela M","year":"2010","unstructured":"de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M, Curado MP. Oral cavity cancer in developed and in developing countries: population-based incidence. Head Neck. 2010, 32:357-67. 10.1002\/hed.21193","journal-title":"Head Neck"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Argiris A","year":"2008","unstructured":"Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008, 371:1695-709. 10.1016\/S0140-6736(08)60728-X","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken JB","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, et al.. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008, 359:1116-27. 10.1056\/NEJMoa0802656","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness B","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, et al.. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019, 394:1915-28. 10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris RL","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al.. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016, 375:1856-67. 10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00890-1","article-title":"When less may be enough: dose selection strategies for immune checkpoint inhibitors focusing on AntiPD-(L)1 agents","volume":"17","author":"Araujo DV","year":"2022","unstructured":"Araujo DV, Uchoa B, Soto-Castillo JJ, Furlan LL, Oliva M. When less may be enough: dose selection strategies for immune checkpoint inhibitors focusing on AntiPD-(L)1 agents. Target Oncol. 2022, 17:253-70. 10.1007\/s11523-022-00890-1","journal-title":"Target Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan D","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000, 105:1045-7. 10.1172\/JCI9872","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.05.019","article-title":"Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer","volume":"40","author":"Guardiola E","year":"2004","unstructured":"Guardiola E, Peyrade F, Chaigneau L, et al.. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004, 40:2071-6. 10.1016\/j.ejca.2004.05.019","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres D","year":"2004","unstructured":"Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004, 22:77-85. 10.1200\/JCO.2004.06.075","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01076","article-title":"Phase I\/II study of palliative triple metronomic chemotherapy in platinum-refractory\/early-failure oral cancer","volume":"37","author":"Patil VM","year":"2019","unstructured":"Patil VM, Noronha V, Joshi A, et al.. Phase I\/II study of palliative triple metronomic chemotherapy in platinum-refractory\/early-failure oral cancer. J Clin Oncol. 2019, 37:3032-41. 10.1200\/JCO.19.01076","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil VM","year":"2023","unstructured":"Patil VM, Noronha V, Menon N, et al.. Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol. 2023, 41:222-32. 10.1200\/JCO.22.01015","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.4099","article-title":"Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer","volume":"30","author":"Gillison ML","year":"2012","unstructured":"Gillison ML, Zhang Q, Jordan R, et al.. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012, 30:2102-11. 10.1200\/JCO.2011.38.4099","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2021.2403","article-title":"Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent\/metastatic head and neck cancer","volume":"15","author":"Geraghty L","year":"2021","unstructured":"Geraghty L, Schultz TE, Hoffman SE, Porter K, Issa M, Karivedu V, Bonomi M. Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent\/metastatic head and neck cancer. Mol Clin Oncol. 2021, 15:240. 10.3892\/mco.2021.2403","journal-title":"Mol Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"ASCO clinical practice guideline: management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. ASCO clinical practice guideline: management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas B","year":"2017","unstructured":"Lacas B, Bourhis J, Overgaard J, et al.. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017, 18:1221-37. 10.1016\/S1470-2045(17)30458-8","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.06.015","article-title":"Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?","volume":"256","author":"Specenier PM","year":"2007","unstructured":"Specenier PM, Vermorken JB. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?. Cancer Lett. 2007, 256:166-77. 10.1016\/j.canlet.2007.06.015","journal-title":"Cancer Lett"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012, 366:2443-54. 10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi L","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017, 17:97-111. 10.1038\/nri.2016.107","journal-title":"Nat Rev Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00233-7","article-title":"The EGFR as a target for anticancer therapy-focus on cetuximab","volume":"37 Suppl 4","author":"Baselga J","year":"2001","unstructured":"Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer. 2001, 37 Suppl 4:S16-22. 10.1016\/s0959-8049(01)00233-7","journal-title":"Eur J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503656-biosimilar-nivolumab-based-combination-therapy-in-advanced-oral-cavity-squamous-cell-carcinoma-a-real-world-case-series-of-five-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:17:58Z","timestamp":1783351078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503656-biosimilar-nivolumab-based-combination-therapy-in-advanced-oral-cavity-squamous-cell-carcinoma-a-real-world-case-series-of-five-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.112146","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}